Clinical Research Directory
Browse clinical research sites, groups, and studies.
Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
Sponsor: Johns Hopkins University
Summary
In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.
Key Details
Gender
All
Age Range
1 Year - 55 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-05-19
Completion Date
2027-10-15
Last Updated
2025-06-05
Healthy Volunteers
No
Conditions
Interventions
Omalizumab
omalizumab injections
Locations (1)
Johns Hopkins
Baltimore, Maryland, United States